RRM1在胃腺癌中的表达及其临床病理意义

doi:10.3760/cma.j.issn.1673-422X.2016.05.006

摘要/Abstract

摘要： 目的探讨人核苷酸还原酶大亚基M1（RRM1）在胃腺癌组织中的表达及其临床意义。方法采用免疫组织化学方法检测88例胃腺癌组织及20例正常胃组织中RRM1的表达水平，分析RRM1的表达与胃腺癌临床病理特征的关系。结果RRM1在胃腺癌组织中阳性表达率为83.0%(73/88)，在正常胃组织中不表达。RRM1的阳性表达与胃腺癌患者的年龄(χ2=0.352，P=0.553)、性别(χ2=0.493，P=0.482)、肿瘤浸润深度(χ2=0.007，P=0.933)、淋巴结转移(χ2=0.121，P=0.728)及远处转移（P=0.415）无关，而与临床分期(χ2=5.733，P=0.017)、肿瘤分化程度(χ2=7.740，P=0.021)存在相关性。结论RRM1在大多数胃腺癌组织中呈阳性表达，与临床分期和分化程度相关，检测胃腺癌组织中RRM1的表达水平有助于确定诊断及判断肿瘤的恶性程度，并且对胃腺癌患者的个体化治疗及估计预后具有潜在的指导意义。

关键词: 胃肿瘤, 免疫组织化学, 核苷酸还原酶大亚基M1

Abstract: ObjectiveTo investigate the expression of human ribonucleotide reductase large subunit M1 (RRM1) in the patients with gastric adenocarcinoma and its clinical significance. MethodsThe expressions of RRM1 were detected in 88 cases of gastric adenocarcinoma and 20 cases of normal gastric tissues by immunohistochemical method. The correlations between the expression of RRM1 and clinicopathological characteristics were analyzed. ResultsThe positive expression rate of RRM1 in gastric adenocarcinoma was 83.0% (73/88). And RRM1 was negative in the entire normal gastric tissues. The positive expression of RRM1 was not associated with patient′s age (χ2=0.352, P=0.553), gender (χ2=0.493, P=0.482), depth of tumor infiltration depth (χ2=0.007, P=0.933), lymph nodes metastasis (χ2=0.121, P=0.728) and distant metastasis (P=0.415). But it was related to the degree of tumor differentiation (χ2=7.740, P=0.021) and clinical stage (χ2=5.733, P=0.017). ConclusionThe expression of RRM1 is positive expression in most gastric adenocarcinoma, and is associated with the degree of tumor differentiation and clinical stage. It is of great significance to detect the expression of RRM1 in gastric adenocarcinoma for confirming the diagnosis and judging malignant degree of the tumor. It also may have potential value in choosing the best therapeutic scheme and estimating prognosis.

Key words: Stomach neoplasms, Immunohistochemistry, Ribonucleotide reductase large subunit M1

林陈石,杨继元. RRM1在胃腺癌中的表达及其临床病理意义[J]. 国际肿瘤学杂志, 2016, 43(5): 343-345.

Lin Chenshi, Yang Jiyuan. Expression of RRM1 in gastric adenocarcinoma and its relationship with clinical pathological characteristics[J]. Journal of International Oncology, 2016, 43(5): 343-345.

参考文献

［1］ Jemal A, Bray F, Center MM, et al. Global cancer statistics［J］. CA Cancer J Clin, 2011, 61(2): 69-90. DOI: 10.3322/caac.20107. ［2］ Jordheim LP, Seve P, Tredan O, et al. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer［J］. Lancet Oncol, 2011, 12(7): 693-702. DOI: 10.1016/S14702045(10)702448. ［3］ Furuta E, Okuda H, Kobayashi A, et al. Metabolic genes in cancer: their roles in tumor progression and clinical implications［J］. Biochim Biophys Acta, 2010, 1805(2): 141-152. DOI: 10.1016/j.bbcan.2010.01.005. ［4］李明显, 夏传生, 李娜萍. ERCC1和RRM1在NSCLC中的表达及其病理临床意义［J］. 中国组织化学与细胞化学杂志, 2011, 20(2): 135-139. ［5］ Wang QC, Liu XY, Zhou JC, et al. Ribonucleotide reductase large subunit M1 predicts poor survival due to modulation of proliferative and invasive ability of gastric cancer［J］. PLoS One, 2013, 8(7): e70191. DOI: 10.1371/journal.pone.0070191. ［6］杨倩, 陈晓宇, 彭延申, 等. 抑癌基因RRM1在胃癌发生、发展中的表达及其临床意义［J］. 胃肠病学, 2012, 17(10): 587-591. ［7］ Tanwar PS, KanekoTarui T, Lee HJ, et al. PTEN loss and HOXA10 expression are associated with ovarian endometrioid adenocarcinoma differentiation and progression［J］. Carcinogenesis, 2013, 34(4): 893-901. DOI: 10.1093/carcin/bgs405. ［8］ Mulholland DJ, Kobayashi N, Ruscetti M, et al. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells［J］. Cancer Res, 2012, 72(7): 1878-1889. DOI: 10.1158/00085472.CAN113132. ［9］ Lee JJ, Maeng CH, Baek SK, et al. The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabinebased chemotherapy in advanced nonsmall cell lung cancer (NSCLC)［J］. Lung Cancer, 2010, 70(2): 205-210. DOI: 10.1016/j.lungcan.2010.02.005. ［10］ Uchibori K, Kasamatsu A, Sunaga M, et al. Establishment and characterization of two 5fluorouracilresistant hepatocellular carcinoma cell lines［J］. Int J Oncol, 2012, 40(4): 1005-1010. DOI: 10.3892/ijo.2011.1300. ［11］ Kurata N, Fujta H, Ohuchida K, et al. Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5fluorouracil［J］. Int J Oncol, 2011, 39(2): 473-482. DOI: 10.3892/ijo.2011.1058.

[1]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[2]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[3]	解淑萍, 孙亚红, 汪超. 早期肿瘤标志物联合NLR、PLR预测胃癌免疫治疗疗效[J]. 国际肿瘤学杂志, 2024, 51(3): 157-165.
[4]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[5]	邵慧芳, 王学红, 芦永福. CST1在胃癌进展中的作用机制及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 489-492.
[6]	朱思雨, 王学红, 李文茜, 刘曙. 胃癌患者血清FABP1水平及其与幽门螺杆菌感染的关系[J]. 国际肿瘤学杂志, 2023, 50(6): 336-341.
[7]	杨娅, 王慧礼, 刘艳, 郭金凤, 王春霞, 吕敏, 山长平. GCSH基因在胃癌SNU-1细胞增殖和凋亡中的作用研究[J]. 国际肿瘤学杂志, 2023, 50(5): 257-262.
[8]	全祯豪, 徐飞鹏, 黄哲, 黄先进, 陈日红, 孙开裕, 胡旭, 林琳. 沉默lncRNA FTX通过miR-22-3p/NLRP3炎症体通路抑制胃癌细胞增殖[J]. 国际肿瘤学杂志, 2023, 50(4): 202-207.
[9]	姬薇, 关泉林, 陈雅蕊, 焦福智, 罗倩文. 血脂水平与胃癌的相关性[J]. 国际肿瘤学杂志, 2023, 50(3): 183-185.
[10]	范珊琳, 汪品秀, 孔飞, 周玉洁, 袁文臻. 胃癌新辅助化疗后肿瘤退缩分级预测因素的研究进展[J]. 国际肿瘤学杂志, 2023, 50(2): 112-116.
[11]	廖利华, 王少洪, 陈洪才, 赵勇强. 细胞蜡块免疫组织化学与胸腔积液CRKL、MIC-1诊断恶性胸腔积液的价值[J]. 国际肿瘤学杂志, 2023, 50(2): 71-75.
[12]	杨俊, 李荣, 曾建昌. 复方苦参注射液联合SOX方案治疗老年晚期胃癌的临床疗效[J]. 国际肿瘤学杂志, 2023, 50(2): 82-86.
[13]	邓莉莉, 段星宇, 李保中. HER2靶向药物及其联合治疗方案在胃及食管胃结合部腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 751-757.
[14]	李佳宜, 王跃, 尚兰兰, 徐兴, 赵岩. 人工智能技术在胃癌诊断与治疗中的实践与展望[J]. 国际肿瘤学杂志, 2023, 50(11): 677-682.
[15]	于晓鹏, 冯青青, 赵文飞, 赵文文, 魏红梅. 靶向治疗联合免疫检查点抑制剂在HER2阳性进展期胃癌中的应用[J]. 国际肿瘤学杂志, 2023, 50(10): 631-635.